This document describes the state of knowledge of the adverse outcome pathway (AOP)
for skin sensitisation initiated by covalent binding to proteins, assesses the weight-of-evidence
supporting the AOP, identifies the key events, and identifies databases containing
test results related to those key events. AOPs can be incorporated into chemical categories-based
assessments or integrated approaches for testing and assessment.